Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: adult stem cell therapies - Pharmascience

Drug Profile

Research programme: adult stem cell therapies - Pharmascience

Alternative Names: Adult stem cell therapies research programme - Pharmascience

Latest Information Update: 02 Jun 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aegera Therapeutics; The Hospital for Sick Children
  • Developer Aegera Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Heart failure; Neurological disorders; Pancreatic disorders

Most Recent Events

  • 02 Nov 2004 Aegera Therapeutics and The Hospital for Sick Children have entered into an agreement to combine their intellectual portfolios regarding the development of skin-derived precursors in Canada
  • 07 Nov 2002 Early research in Heart failure in Canada (unspecified route)
  • 07 Nov 2002 Early research in Heart failure in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top